Hints and tips:
...Ashish Gupta, head of Indian equity research at Credit Suisse, said India’s rising caseload ruled out a V-shaped rebound....
US defence secretary Mark Esper breaks with Trump over sending troops to quell protests
...Major pharmaceutical groups are focusing on becoming one of the top three players in whatever category they operate....
...Rounding out the top three is pharmaceutical group AbbVie, which generated roughly $311m in fees for its investment bankers last year. Much of that was tied to its $84bn takeover of Allergan....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...The $90bn acquisition of Celgene is one of the largest pharmaceutical deals in history, as BMS aims to create a world leader in oncology....
...Wellington Management also had said it would vote against the Celgene acquisition....
...Activist investor Starboard Value became the latest investor to publicly criticise Bristol-Myers Squibb’s $90bn takeover of Celgene, putting in jeopardy one of the largest pharmaceutical deals in history...
...US pharmaceuticals group Bristol-Myers Squibb defended its $90bn takeover of rival drugmaker Celgene on Wednesday, urging its shareholders to vote in favour of a deal that it characterised as the “best path...
...Some analysts expect the Celgene deal to push other large pharmaceutical companies to hunt for more acquisitions to bolster their cancer drug pipelines....
...The takeover of Celgene, announced in early January, would be one of the biggest pharmaceuticals deals of all time....
...pharmaceutical industry history....
...Earlier this year they advised Celgene on its $90bn sale to Bristol-Myers Squibb. Who needs time to relax when these fees are at stake?...
...Bankers and lawyers worked with haste to sew up the transaction between the two pharmaceutical groups after Bristol-Myers Squibb’s chief executive proposed a buyout to the head of Celgene over dinner on...
...Bristol-Myers Squibb, the US drugmaker, has struck one of the largest pharmaceutical deals in history, agreeing to buy Celgene in a cash-and-stock deal valuing the rival drugmaker at roughly $90bn including...
...The intervention by the Boston-based firm, which manages about $1tn in assets, could kill one of the largest ever deals in the pharmaceuticals sector....
...Last year he advised Swiss pharmaceutical group Novartis on its purchase of AveXis, structured General Electric’s $11bn locomotive combination with Wabtec, and offered advice on the $6.4bn sale of ABB’s...
...Last week he snared his biggest target since starting his namesake firm: advising US drugmaker Bristol-Myers Squibb on its $90bn takeover of biotech company Celgene....
...He added: “[The FDA] kinda said ‘what happened guys, this isn’t what we usually expect from Celgene?’ And we had to say, you know, ‘mea culpa it’s on us’.”...
...That’s not the case for the leaders of some of the world’s largest pharmaceutical groups. Especially for those executives hunting for new cancer drugs....
...Robert Hugin, the former Celgene chief executive who signed off most of the Revlimid increases, is now a Republican candidate for the Senate. For some reason, he has escaped Mr Trump’s wrath....
...A spokesperson for Celgene declined to comment....
...Celgene, the biotech group, reported fourth quarter earnings and revenues ahead of expectations as it tries to rebuild investor trust following a difficult few months....
...In sifting through the S&P 500, it has chosen to only include companies with 0-45 per cent tax rates, so as to eliminate bizarre outliers such as pharmaceutical company Eli Lilly, who reported a tax rate...
International Edition